Name | JNJ-67856633 |
---|
Description | JNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric MALT1 protease inhibitor. JNJ-67856633 in some cases lead to tumor stasis[1][2][3]. |
---|---|
Related Catalog | |
Target |
MALT1 protease[1][2][3] |
In Vitro | JNJ-67856633 is effective and highly bioavailable in both mouse and rat tumors, and in some cases led to tumor stasis. JNJ-67856633 leads to potent in vivo pharmacodynamic shutdown in CD79b- as well as CARD11-mutant ABC-DLBCL models as measured by serum IL10 or uncleaved BCL10 levels in tumors[1][3]. |
In Vivo | Dose dependent inhibition of the generation of Tregs (CD4+CD25+FoxP3+) following CD3/28 stimulation was observed upon treatment with JNJ-67856633 suggesting a potential immune modulatory role of MALT1 inhibition[3]. |
References |
Molecular Formula | C20H11F6N5O2 |
---|---|
Molecular Weight | 467.32 |
Storage condition | -20°C |